Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.45 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1440342 | 1.00 | APLNR (0.45) | APLNRTRPV3TRPA1KCNH2HRH1 | |
| Hydrochloric Acid SCHEMBL1439641 | 0.98 | APLNR (0.44) | APLNRTRPV3TRPA1KCNH2HRH1 | |
| Hydrochloric Acid SCHEMBL1693505 | 0.98 | APLNR (0.44) | APLNRTRPV3TRPA1KCNH2HRH1 | |
| Hydrochloric Acid SCHEMBL1693507 | 0.98 | APLNR (0.44) | APLNRTRPV3TRPA1KCNH2HRH1 | |
| Hydrochloric Acid SCHEMBL3020024 | 0.98 | APLNR (0.44) | APLNRTRPV3TRPA1KCNH2HRH1 | |
| Hydrochloric Acid SCHEMBL1438841 | 0.98 | APLNR (0.44) | APLNRTRPV3TRPA1KCNH2HRH1 | |
| SCHEMBL4026704 | 0.85 | APLNR (0.43) | APLNRTRPV3KCNH2HRH1 | |
| Hydrochloric Acid SCHEMBL3949120 | 0.84 | APLNR (0.42) | APLNR | |
| SCHEMBL31471324 | 0.82 | APLNR (0.41) | APLNR | |
| SCHEMBL3770922 | 0.81 | APLNR (0.45) | APLNRKCNH2HRH1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011029027-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | APLNR 4244/4885TRPV3 4332/4885TRPA1 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.